Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference41 articles.
1. Watts GF, Sullivan DR, Hare DL, Kostner KM, Horton AE, Bell DA, et al. Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia∗. Heart Lung Circ. 2021;30(3):324–49.
2. Hu P, Dharmayat KI, Stevens CAT, Sharabiani MTA, Jones RS, Watts GF, et al. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease. Circulation. 2020;141(22):1742–59.
3. Ademi Z, Marquina C, Zomer E, Bailey C, Owen A, Pang J, et al. The economic impact of familial hypercholesterolemia on productivity. J Clin Lipidol. 2020;14(6):799-806.e3.
4. Patel P, Hu Y, Kolinovsky A, Geng Z, Ruhl J, Krishnamurthy S, et al. Hidden burden of electronic health record-identified familial hypercholesterolemia: clinical outcomes and cost of medical care. J Am Heart Assoc. 2019;8(13): e011822.
5. Araujo LR. Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system. Arch Endocrinol Metab. 2018;62(3):303–8.